摘要
目的建立人血浆中伊马替尼及其代谢物浓度的液相色谱-串联质谱法(LC-MS/MS)测定方法,并评价伊马替尼胶囊的药动学特征及生物等效性。方法 24名男性健康受试者随机分成两组,分别交叉给予伊马替尼受试制剂和参比制剂各400 mg,采用LC-MS/MS测定伊马替尼及伊马替尼代谢物的浓度,色谱柱为Thermo BDS HYPERSIL C18(100 mm×4.6 mm,2.4μm),流动相为甲醇(A)-0.1%甲酸0.2%醋酸铵溶液(B)(55:45,V/V),流速为0.7 mL·min-1;质谱采用电喷雾电离,正离子多离子反应监测模式,检测离子伊马替尼为m/z 494.10→393.85,伊马替尼代谢物为m/z 480.10→393.80,帕洛诺司琼(内标物)为m/z 297.10→109.80,估算伊马替尼及代谢物的药动学参数,评价两种制剂的人体生物等效性。结果伊马替尼受试制剂与参比制剂的各主要药动学参数:tmax分别为(2.8±1.2)h和(3.1±1.1)h,ρmax分别为(1 928.94±478.84) μg·L-1和(1 738.94±237.30) μg·L-1,t1/2分别为(17.65±1.71)h和(17.80±1.99)h,用梯形法计算AUC0-120 h分别为(37 715.80±7 625.84)μg.h.L-1和(33 961.65±6 218.64)μg.h.L-1,其代谢物的药动学参数:tmax分别为(2.8±1.2)h和(2.8±1.1)h,ρmax分别为(194.21±58.85) μg·L-1和(198.16±52.49) μg·L-1,t1/2分别为(37.59±3.53)h和(38.45±5.28)h,用梯形法计算AUC0-120 h分别为(5 274.57±1 379.87)μg.h.L-1和(5 128.31±1 119.75)μg.h.L-1。结论建立的测定方法可用于伊马替尼及其代谢物的药动学研究,伊马替尼两种制剂生物等效。
AIM To establish a LC-MS/MS method for the determination of imatinib and its metabolite in human plasma and to evaluate the pharmacokinetics and bioequivalence of imatinib capsuls in healthy volunteers. METHODS A 400 mg dose of the reference or test capsules were given to 24 healthy male volunteers in a randomized two-way crossover design and the plasma concentration of the drug was assayed by LC-MS/MS. Chromatography separation was carried on a Thermo BDS HYPERSIL C18 (100 mm×4.6 mm, 2.4 μm), with a mobile phase consisting of methanol -0.1% formic acid 0.2%ammonium acetate (55 : 45, V/V), a flow rate of 0.7 mL.min-1. Detection and quantification were performed by mass spectrometric in the multiple reaction monitoring mode with positive electrospray ionization at 494.10-'393.85 for imatinib, 480.10→393.80 for metabolite and 297.10→109.80 for oalonosetron (internal standard)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2013年第2期145-150,共6页
Chinese Journal of New Drugs and Clinical Remedies
基金
国家科技部(2011ZXJ09202-013)
关键词
伊马替尼
代谢物
胶囊
色谱法
高压液相
串联质谱法
药动学
生物等效性
imatinib
metabolite
capsules
chromatography, high pressure liquid
tandem massspectrometry
pharmacokinetics
bioequivalence